Ocera Therapeutics has entered into a technology transfer and license agreement with Roche, including the R&D arm of Genentech, for rights to its Macrocyclic Template Chemistry (MATCH) discovery platform. Ocera will transfer ownership of equipment and materials related the MATCH technology and grant a license to Genentech and Roche for related intellectual property rights, for a one-time payment of $4 million.   “Both the Genentech and Roche research organizations have an interest in t...